| Drug Name |
Fenofibric acid |
| Drug ID |
BADD_D00874 |
| Description |
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362] |
| Indications and Usage |
For use as an adjunctive therapy to diet to: (a) reduce triglyceride levels in adult patients with severe hypertriglyceridemia, and (b) reduce elevated total cholesterol, low-density-lipoprotein (LDL-C), triglycerides, and apolipoprotein B, and to increase high-density-lipoprotein (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). [FDA Label] |
| Marketing Status |
Prescription |
| ATC Code |
Not Available |
| DrugBank ID |
DB13873
|
| KEGG ID |
D11579
|
| MeSH ID |
C006012
|
| PubChem ID |
64929
|
| TTD Drug ID |
D0NF1U
|
| NDC Product Code |
69844-023; 68134-602; 0074-3161; 71511-502; 46708-905; 70436-168; 50090-4373; 66064-1003; 68180-128; 59651-216; 68382-232; 46708-245; 72834-105; 0115-1554; 59651-217; 68543-3162; 62332-244; 69844-022; 69315-281; 72834-035; 71511-501; 70436-169; 68382-233; 50090-5369; 42571-347; 50090-4561; 68134-601; 42571-348; 0115-1555; 46708-244; 69315-282; 24979-112; 17337-0411; 42385-945; 0074-3162; 42385-944; 62332-245; 68543-3161; 24979-109; 68180-129 |
| Synonyms |
fenofibric acid | 2-(4-(4'-chlorophenoxy)phenoxy)propionic acid | fenofibric acid sodium salt | fenofibric acid potassium salt | fenofibric acid, (R)-isomer | HCG 004 |
